Incidence of high altitude cerebral oedema (HACE) ‐ not reported · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Side effects or other adverse events · participants at risk of high altitude illness
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review
Corticosteroid related adverse events · Patients with active Crohn's disease
Budesonide 3 mg showed no clear difference in corticosteroid related adverse events compared with placebo (low certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
Budesonide 6 mg showed no clear difference in continued remission at 3 months compared with placebo (low certainty).
3 findings from 1 review
RR 1.25 [1, 1.58]
6 studies · 540 participants
Low
RR 1.15 [0.95, 1.39]
5 studies · 420 participants
Moderate
RR 1.13 [0.94, 1.35]
5 studies · 420 participants
Moderate
Remission · Participants with Crohn's disease in remission
It is very uncertain whether budesonide 6 mg changes continued remission at 12 months compared with mesalamine 3 g (very low certainty).
1 finding from 1 review
Remission · Participants with Crohn's disease in remission
Budesonide 3 mg probably leads to higher continued remission at 3 months compared with placebo (moderate certainty).
3 findings from 1 review
RR 1.29 [1.01, 1.63]
4 studies · 263 participants
Moderate
RR 1.12 [0.83, 1.51]
3 studies · 180 participants
Moderate
RR 1.08 [0.87, 1.34]
5 studies · 442 participants
Moderate
Clinical improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · active EoE patients
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 15 mg probably leads to higher induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with placebo (moderate certainty).
1 finding from 1 review
Clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐ 8 weeks · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in clinical improvement (decrease in CDAI > 100 or total CDAI <= 150) ‐… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 15 mg showed no clear difference in withdrawal due to adverse events compared with placebo (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
Budesonide 15 mg probably leads to lower withdrawal due to disease worsening compared with placebo (moderate certainty).
1 finding from 1 review